Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations

Fig. 3

Cumulative incidence of clinical failure within 42 days (after PCR-correction) in patients treated with a 3-day dihydroartemisinin-piperaquine course according to K13 allele (wild-type or mutant) and ex vivo piperaquine survival assay (PSA) survival rates of day 0 parasites. The cumulative incidence of clinical failure was significantly higher in patients infected on day 0 by isolates carrying a mutant K13 allele and presenting a PSA survival rate ≥10 % (P <1 × 10–10, log rank test, Hazard Ratio = 14.3, 95 % CI, 4.6–44.6, Fig. 3). The survival proportion at day 42 for those patients was estimated 25.8 % (SD = 7.9 %)

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us